{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:27:07Z","timestamp":1792783627826,"version":"4.5.0"},"reference-count":195,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Amgen (Europe) GmbH"},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bone"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1016\/j.bone.2010.11.020","type":"journal-article","created":{"date-parts":[[2010,12,10]],"date-time":"2010-12-10T04:26:27Z","timestamp":1291955187000},"page":"677-692","source":"Crossref","is-referenced-by-count":612,"title":["Denosumab and bisphosphonates: Different mechanisms of action and effects"],"prefix":"10.1016","volume":"48","author":[{"given":"Roland","family":"Baron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Graham G.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 5","key":"10.1016\/j.bone.2010.11.020_bb0005","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1007\/s00198-003-1477-1","article-title":"Role of bone turnover in microdamage","volume":"14","author":"Schaffler","year":"2003","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2010.11.020_bb0010","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1615\/CritRevEukarGeneExpr.v19.i1.40","article-title":"Molecular mechanisms in coupling of bone formation to resorption","volume":"19","author":"Martin","year":"2009","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"10.1016\/j.bone.2010.11.020_bb0015","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11154-006-9009-x","article-title":"Molecular regulation of osteoclast activity","volume":"7","author":"Bruzzaniti","year":"2006","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.bone.2010.11.020_bb0020","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/0470846658.ch17","article-title":"Clinical disorders of bone resorption","volume":"232","author":"Russell","year":"2001","journal-title":"Novartis Found Symp"},{"key":"10.1016\/j.bone.2010.11.020_bb0025","doi-asserted-by":"crossref","first-page":"5096","DOI":"10.1210\/jc.2005-0396","article-title":"Relationship of volumetric bone density and structural parameters at different skeletal sites to sex steroid levels in women","volume":"90","author":"Khosla","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2010.11.020_bb0030","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1152\/japplphysiol.00564.2003","article-title":"Invited review: pathogenesis of osteoporosis","volume":"95","author":"Seeman","year":"2003","journal-title":"J Appl Physiol"},{"key":"10.1016\/j.bone.2010.11.020_bb0035","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/S0140-6736(10)60320-0","article-title":"Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study","volume":"375","author":"Zebaze","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2010.11.020_bb0040","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1172\/JCI200317215","article-title":"Role of RANK ligand in mediating increased bone resorption in early postmenopausal women","volume":"111","author":"Eghbali-Fatourechi","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bone.2010.11.020_bb0045","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1146\/annurev.immunol.20.100301.064753","article-title":"RANK-L and RANK: T cells, bone loss, and mammalian evolution","volume":"20","author":"Theill","year":"2002","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.bone.2010.11.020_bb0050","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ajhg.2008.06.015","article-title":"Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations","volume":"83","author":"Guerrini","year":"2008","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.bone.2010.11.020_bb0055","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/ng2076","article-title":"Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL","volume":"39","author":"Sobacchi","year":"2007","journal-title":"Nat Genet"},{"key":"10.1016\/j.bone.2010.11.020_bb0060","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1056\/NEJMoa050893","article-title":"Recombinant osteoprotegerin for juvenile Paget's disease","volume":"353","author":"Cundy","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2010.11.020_bb0065","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1359\/jbmr.2001.16.2.348","article-title":"The effect of a single dose of osteoprotegerin in postmenopausal women","volume":"16","author":"Bekker","year":"2001","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.11.020_bb0070","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/345442a0","article-title":"The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene","volume":"345","author":"Yoshida","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.bone.2010.11.020_bb0075","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/BF02563795","article-title":"Murine osteoblastlike cells and the osteogenic cell MC3T3-E1 release a macrophage colony-stimulating activity in culture","volume":"41","author":"Elford","year":"1987","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.bone.2010.11.020_bb0080","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.bone.2010.11.020_bb0085","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","article-title":"Osteoclast differentiation and activation","volume":"423","author":"Boyle","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.bone.2010.11.020_bb0090","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.bone.2006.09.023","article-title":"The molecular understanding of osteoclast differentiation","volume":"40","author":"Asagiri","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.bone.2010.11.020_bb0095","doi-asserted-by":"crossref","first-page":"4742","DOI":"10.4049\/jimmunol.181.7.4742","article-title":"Inhibitory immunoglobulin-like receptors LILRB and PIR-B negatively regulate osteoclast development","volume":"181","author":"Mori","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.bone.2010.11.020_bb0100","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/nrrheum.2009.217","article-title":"Osteoimmunology and the effects of the immune system on bone","volume":"5","author":"Takayanagi","year":"2009","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.bone.2010.11.020_bb0105","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/16852","article-title":"OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis","volume":"397","author":"Kong","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.bone.2010.11.020_bb0110","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.cytogfr.2004.06.004","article-title":"The molecular triad OPG\/RANK\/RANKL: involvement in the orchestration of pathophysiological bone remodeling","volume":"15","author":"Theoleyre","year":"2004","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.bone.2010.11.020_bb0115","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s12178-009-9046-7","article-title":"RANK, RANKL and osteoprotegerin in bone biology and disease","volume":"2","author":"Wright","year":"2009","journal-title":"Curr Rev Musculoskelet Med"},{"key":"10.1016\/j.bone.2010.11.020_bb0120","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1210\/er.2007-0014","article-title":"Receptor activator of nuclear factor \u03baB ligand and osteoprotegerin regulation of bone remodeling in health and disease","volume":"29","author":"Kearns","year":"2008","journal-title":"Endocr Rev"},{"key":"10.1016\/j.bone.2010.11.020_bb0125","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1084\/jem.178.5.1733","article-title":"Macrophage colony-stimulating factor stimulates survival and chemotactic behavior in isolated osteoclasts","volume":"178","author":"Fuller","year":"1993","journal-title":"J Exp Med"},{"key":"10.1016\/j.bone.2010.11.020_bb0130","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1083\/jcb.145.3.527","article-title":"The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts","volume":"145","author":"Burgess","year":"1999","journal-title":"J Cell Biol"},{"key":"10.1016\/j.bone.2010.11.020_bb0135","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0002-9440(10)64556-7","article-title":"Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo","volume":"157","author":"Lacey","year":"2000","journal-title":"Am J Pathol"},{"key":"10.1016\/j.bone.2010.11.020_bb0140","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1084\/jem.190.2.293","article-title":"Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption","volume":"190","author":"Niida","year":"1999","journal-title":"J Exp Med"},{"key":"10.1016\/j.bone.2010.11.020_bb0145","doi-asserted-by":"crossref","first-page":"14016","DOI":"10.1073\/pnas.0503544102","article-title":"VEGF receptor 1 signaling is essential for osteoclast development and bone marrow formation in colony-stimulating factor 1-deficient mice","volume":"102","author":"Niida","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bone.2010.11.020_bb0150","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1210\/jcem-55-2-219","article-title":"Quantitative bone histomorphometry in humoral hypercalcemia of malignancy: uncoupling of bone cell activity","volume":"55","author":"Stewart","year":"1982","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2010.11.020_bb0155","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.molmed.2004.12.004","article-title":"Osteoclast-derived activity in the coupling of bone formation to resorption","volume":"11","author":"Martin","year":"2005","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.bone.2010.11.020_bb0160","doi-asserted-by":"crossref","first-page":"28164","DOI":"10.1074\/jbc.M110.101964","article-title":"Are osteoclasts needed for the bone anabolic response to PTH? A study of intermittent PTH with denosumab or alendronate in knock-in mice expressing humanized RANKL","volume":"285","author":"Pierroz","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bone.2010.11.020_bb0165","doi-asserted-by":"crossref","first-page":"20764","DOI":"10.1073\/pnas.0805133106","article-title":"Regulation of bone formation by osteoclasts involves Wnt\/BMP signaling and the chemokine sphingosine-1-phosphate","volume":"105","author":"Pederson","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bone.2010.11.020_bb0170","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.cmet.2006.05.012","article-title":"Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis","volume":"4","author":"Zhao","year":"2006","journal-title":"Cell Metab"},{"key":"10.1016\/j.bone.2010.11.020_bb0175","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1138\/20100463","article-title":"EPHs and ephrins: many pathways to regulate osteoblasts and osteoclasts","volume":"7","author":"Sims","year":"2010","journal-title":"IBMS BoneKEy"},{"key":"10.1016\/j.bone.2010.11.020_bb0180","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.bone.2009.03.671","article-title":"Local communication on and within bone controls bone remodeling","volume":"44","author":"Henriksen","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.bone.2010.11.020_bb0185","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1359\/jbmr.090315","article-title":"Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis","volume":"24","author":"Recker","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.11.020_bb0190","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1002\/jbmr.149","article-title":"Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies","volume":"25","author":"Reid","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.11.020_bb0195","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","article-title":"Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy","volume":"19","author":"Russell","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2010.11.020_bb0200","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1172\/JCI114100","article-title":"Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow","volume":"83","author":"Hughes","year":"1989","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bone.2010.11.020_bb0205","first-page":"27","article-title":"Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix","volume":"1","author":"Boonekamp","year":"1986","journal-title":"Bone Miner"},{"key":"10.1016\/j.bone.2010.11.020_bb0210","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/j.bone.2010.01.152","article-title":"Bisphosphonates affect human osteoclast development in vitro","volume":"46","author":"Mabilleau","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.bone.2010.11.020_bb0215","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1126\/science.165.3899.1264","article-title":"Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo","volume":"165","author":"Francis","year":"1969","journal-title":"Science"},{"key":"10.1016\/j.bone.2010.11.020_bb0220","series-title":"Symposium CEMO (Centre d'Etude des Maladies Ost\u00e9o-articulaires de Gen\u00e8ve) IV: diphosphonates and bone, Nyon (Switzerland), November 1\u20134, 1981","first-page":"1","article-title":"The physical chemistry of the disphosphonates \u2014 its relationship to their medical activity","author":"Benedict","year":"1982"},{"key":"10.1016\/j.bone.2010.11.020_bb0225","series-title":"Bisphosphonate on bones","first-page":"125","article-title":"Bisphosphonate therapy in acute and chronic bone loss: physical chemical considerations in bisphosphonate-related therapies","author":"Ebrahimpour","year":"1995"},{"key":"10.1016\/j.bone.2010.11.020_bb0230","series-title":"Bisphosphonates in bone disease: from the laboratory to the patient","author":"Fleisch","year":"2000"},{"key":"10.1016\/j.bone.2010.11.020_bb0235","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/jbm.a.31599","article-title":"Bisphosphonate binding affinity as assessed by inhibition of carbonated apatite dissolution in vitro","volume":"85","author":"Henneman","year":"2008","journal-title":"J Biomed Mater Res A"},{"key":"10.1016\/j.bone.2010.11.020_bb0240","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.bone.2005.05.003","article-title":"Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite","volume":"38","author":"Nancollas","year":"2006","journal-title":"Bone"},{"key":"10.1016\/j.bone.2010.11.020_bb0245","first-page":"233","article-title":"Mechanisms of action of etidronate and other bisphosphonates","volume":"9","author":"Ebetino","year":"1998","journal-title":"Rev Contemp Pharmacother"},{"key":"10.1016\/j.bone.2010.11.020_bb0250","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1172\/JCI115539","article-title":"Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure","volume":"88","author":"Sato","year":"1991","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bone.2010.11.020_bb0255","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1124\/mol.105.020776","article-title":"Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis","volume":"69","author":"Thompson","year":"2006","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.bone.2010.11.020_bb0260","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.semcdb.2008.08.004","article-title":"Vesicular trafficking in osteoclasts","volume":"19","author":"Coxon","year":"2008","journal-title":"Semin Cell Dev Biol"},{"key":"10.1016\/j.bone.2010.11.020_bb0265","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1002\/jbmr.5650111016","article-title":"Dissociation of binding and antiresorptive properties of hydroxybisphosphonates by substitution of the hydroxyl with an amino group","volume":"11","author":"van Beek","year":"1996","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.11.020_bb0270","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1002\/1529-0131(200109)44:9<2201::AID-ART374>3.0.CO;2-E","article-title":"The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis","volume":"44","author":"Frith","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.bone.2010.11.020_bb0275","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":"Osteoprotegerin: a novel secreted protein involved in the regulation of bone density","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.bone.2010.11.020_bb0280","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s00198-007-0363-7","article-title":"The RANKL inhibitor OPG-Fc increases cortical and trabecular bone mass in young gonad-intact cynomolgus monkeys","volume":"18","author":"Ominsky","year":"2007","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2010.11.020_bb0285","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/cncr.11138","article-title":"A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases","volume":"97","author":"Body","year":"2003","journal-title":"Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.bone.2010.11.020_bb0290","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1186\/ar2171","article-title":"Clinical development of anti-RANKL therapy","volume":"9","author":"Schwarz","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.bone.2010.11.020_bb0295","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cncr.11134","article-title":"RANK-Fc: a therapeutic antagonist for RANK-L in myeloma","volume":"97","author":"Sordillo","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.bone.2010.11.020_bb0300","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2010.11.020_bb0305","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S1359-6446(05)03638-X","article-title":"Elimination mechanisms of therapeutic monoclonal antibodies","volume":"11","author":"Tabrizi","year":"2006","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.bone.2010.11.020_bb0310","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1359\/jbmr.081112","article-title":"Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine\/human) RANKL","volume":"24","author":"Kostenuik","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.11.020_bb0315","doi-asserted-by":"crossref","first-page":"14363","DOI":"10.1074\/jbc.273.23.14363","article-title":"Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL","volume":"273","author":"Emery","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bone.2010.11.020_bb0320","author":"Amgen Europe"},{"key":"10.1016\/j.bone.2010.11.020_bb0325","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1056\/NEJMoa0802633","article-title":"Giant osteoclast formation and long-term oral bisphosphonate therapy","volume":"360","author":"Weinstein","year":"2009","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.bone.2010.11.020_bb0330","first-page":"S475","article-title":"OPG prevents osteopenia in arthritic rats via different mechanisms than bisphosphonate therapy","volume":"22","author":"Stolina","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.11.020_bb0335","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.bone.2006.03.016","article-title":"OPG\/membranous\u2013RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation","volume":"39","author":"Tat","year":"2006","journal-title":"Bone"},{"key":"10.1016\/j.bone.2010.11.020_bb0340","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1359\/jbmr.070508","article-title":"Further insights in the mechanisms of interleukin-1\u03b2 stimulation of osteoprotegerin in osteoblast-like cells","volume":"22","author":"Lambert","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.11.020_bb0345","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1359\/jbmr.060915","article-title":"Co-treatment of PTH with osteoprotegerin or alendronate increases its anabolic effect on the skeleton of oophorectomized mice","volume":"22","author":"Samadfam","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.11.020_bb0350","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.2174\/1381612033453640","article-title":"New insights into the molecular mechanisms of action of bisphosphonates","volume":"9","author":"Rogers","year":"2003","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.bone.2010.11.020_bb0355","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1359\/jbmr.071207","article-title":"Long-term protective effects of zoledronic acid on cancellous and cortical bone in the ovariectomized rat","volume":"23","author":"Gasser","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.11.020_bb0360","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bone.2008.09.017","article-title":"Do osteocytes contribute to bone mineral homeostasis? Osteocytic osteolysis revisited","volume":"44","author":"Teti","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.bone.2010.11.020_bb0365","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.bone.2007.12.224","article-title":"Osteocytes, mechanosensing and Wnt signaling","volume":"42","author":"Bonewald","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.bone.2010.11.020_bb0370","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1242\/dev.025825","article-title":"BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway","volume":"135","author":"Kamiya","year":"2008","journal-title":"Development"},{"key":"10.1016\/j.bone.2010.11.020_bb0375","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1128\/MCB.01428-09","article-title":"Osteocyte Wnt\/beta-catenin signaling is required for normal bone homeostasis","volume":"30","author":"Kramer","year":"2010","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.bone.2010.11.020_bb0380","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1359\/jbmr.090215","article-title":"One year of transgenic overexpression of osteoprotegerin in rats suppressed bone resorption and increased vertebral bone volume, density, and strength","volume":"24","author":"Ominsky","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.11.020_bb0385","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.bone.2009.06.011","article-title":"Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin","volume":"45","author":"Li","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.bone.2010.11.020_bb0390","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1359\/jbmr.060107","article-title":"Osteocyte apoptosis is induced by weightlessness in mice and precedes osteoclast recruitment and bone loss","volume":"21","author":"Aguirre","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.11.020_bb0395","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1196\/annals.1402.018","article-title":"Osteocytes as dynamic multifunctional cells","volume":"1116","author":"Bonewald","year":"2007","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.bone.2010.11.020_bb0400","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1172\/JCI6800","article-title":"Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin","volume":"104","author":"Plotkin","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bone.2010.11.020_bb0405","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.bone.2006.02.060","article-title":"Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts\/osteocytes with novel analogs","volume":"39","author":"Plotkin","year":"2006","journal-title":"Bone"},{"key":"10.1016\/j.bone.2010.11.020_bb0410","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1359\/jbmr.080617","article-title":"Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo","volume":"23","author":"Plotkin","year":"2008","journal-title":"J Bone Miner Res"},{"issue":"Suppl 1","key":"10.1016\/j.bone.2010.11.020_bb0415","first-page":"S4","article-title":"A bisphosphonate analog that lacks anti-remodeling activity prevents osteocyte and osteoblast apoptosis in vivo","volume":"22","author":"Plotkin","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.11.020_bb0420","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1016\/j.lfs.2004.04.048","article-title":"Fas\/CD95 is associated with glucocorticoid-induced osteocyte apoptosis","volume":"75","author":"Kogianni","year":"2004","journal-title":"Life Sci"},{"key":"10.1016\/j.bone.2010.11.020_bb0425","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.bone.2006.12.052","article-title":"Risedronate and alendronate suppress osteocyte apoptosis following cyclic fatigue loading","volume":"40","author":"Follet","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.bone.2010.11.020_bb0430","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.2174\/138161210793563635","article-title":"Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages","volume":"16","author":"Roelofs","year":"2010","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.bone.2010.11.020_bb0435","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.bone.2007.04.179","article-title":"Individual and combined effects of exercise and alendronate on bone mass and strength in ovariectomized rats","volume":"41","author":"Fuchs","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.bone.2010.11.020_bb0440","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s00223-009-9269-z","article-title":"Does exercise modify the effects of zoledronic acid on bone mass, microarchitecture, biomechanics, and turnover in ovariectomized rats?","volume":"85","author":"Lespessailles","year":"2009","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.bone.2010.11.020_bb0445","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.clinbiomech.2010.08.014","article-title":"Combined effects of zoledronate and mechanical stimulation on bone adaptation in axially loaded mouse tibia","volume":"26","author":"Stadelmann","year":"2011","journal-title":"Clin Biomech"},{"key":"10.1016\/j.bone.2010.11.020_bb0450","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1101\/gad.13.18.2412","article-title":"RANK is essential for osteoclast and lymph node development","volume":"13","author":"Dougall","year":"1999","journal-title":"Genes Dev"},{"key":"10.1016\/j.bone.2010.11.020_bb0455","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1084\/jem.189.7.1025","article-title":"TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation","volume":"189","author":"Bachmann","year":"1999","journal-title":"J Exp Med"},{"key":"10.1016\/j.bone.2010.11.020_bb0460","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S1074-7613(03)00326-1","article-title":"Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin","volume":"19","author":"Ashcroft","year":"2003","journal-title":"Immunity"},{"key":"10.1016\/j.bone.2010.11.020_bb0465","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1136\/gut.2003.035113","article-title":"CD4+CD45RBHi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin","volume":"54","author":"Byrne","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.bone.2010.11.020_bb0470","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/46303","article-title":"Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand","volume":"402","author":"Kong","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.bone.2010.11.020_bb0475","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/S0002-9440(10)64417-3","article-title":"Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis","volume":"161","author":"Romas","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1016\/j.bone.2010.11.020_bb0480","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1002\/art.21021","article-title":"Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models","volume":"52","author":"Schett","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.bone.2010.11.020_bb0485","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/art.10097","article-title":"Tumor necrosis factor \u03b1-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin","volume":"46","author":"Redlich","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.bone.2010.11.020_bb0490","doi-asserted-by":"crossref","first-page":"R187","DOI":"10.1186\/ar2879","article-title":"RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNF-alpha or anti-IL-1 therapies","volume":"11","author":"Stolina","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.bone.2010.11.020_bb0495","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.bone.2009.10.028","article-title":"RANKL-targeted therapy inhibits bone resorption in experimental Staphylococcus aureus-induced arthritis","volume":"46","author":"Verdrengh","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.bone.2010.11.020_bb0500","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00198-010-1326-y","article-title":"Do RANKL inhibitors (denosumab) affect inflammation and immunity?","volume":"22","author":"Ferrari-Lacraz","year":"2010","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2010.11.020_bb0505","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2010.11.020_bb0510","first-page":"144","article-title":"Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention","volume":"7","author":"Bock","year":"2007","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"10.1016\/j.bone.2010.11.020_bb0515","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/art.21918","article-title":"Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study","volume":"54","author":"Delmas","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.bone.2010.11.020_bb0520","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2165\/00002018-200730090-00003","article-title":"Safety considerations with bisphosphonates for the treatment of osteoporosis","volume":"30","author":"Strampel","year":"2007","journal-title":"Drug Saf"},{"key":"10.1016\/j.bone.2010.11.020_bb0525","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1359\/JBMR.0301230","article-title":"Statins prevent bisphosphonate-induced \u03b3, \u03b4-T-cell proliferation and activation in vitro","volume":"19","author":"Thompson","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.11.020_bb0530","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1476-5381.2009.00160.x","article-title":"Zoledronic acid induces formation of a pro-apoptotic ATP analogue and isopentenyl pyrophosphate in osteoclasts in vivo and in MCF-7 cells in vitro","volume":"157","author":"Raikkonen","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bone.2010.11.020_bb0535","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1138\/20100450","article-title":"Nitrogen-containing bisphosphonates and human \u03b3\u03b4 T cells","volume":"7","author":"Benzaid","year":"2010","journal-title":"IBMS BoneKEy"},{"key":"10.1016\/j.bone.2010.11.020_bb0540","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1359\/jbmr.081016","article-title":"Atorvastatin may have no effect on acute phase reaction in children after intravenous bisphosphonate infusion","volume":"24","author":"Srivastava","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.11.020_bb0545","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1161\/01.ATV.20.8.1926","article-title":"Progression of aortic calcification is associated with metacarpal bone loss during menopause: a population-based longitudinal study","volume":"20","author":"Hak","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.bone.2010.11.020_bb0550","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1359\/jbmr.070903","article-title":"Calcifications in the abdominal aorta predict fractures in men: MINOS study","volume":"23","author":"Szulc","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.11.020_bb0555","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1101\/gad.12.9.1260","article-title":"Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification","volume":"12","author":"Bucay","year":"1998","journal-title":"Genes Dev"},{"key":"10.1016\/j.bone.2010.11.020_bb0560","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1161\/01.ATV.0000236428.91125.e6","article-title":"Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE\u2212\/\u2212 mice","volume":"26","author":"Bennett","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.bone.2010.11.020_bb0565","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2353\/ajpath.2009.080957","article-title":"Inhibition of receptor activator of NF-\u03baB ligand by denosumab attenuates vascular calcium deposition in mice","volume":"175","author":"Helas","year":"2009","journal-title":"Am J Pathol"},{"key":"10.1016\/j.bone.2010.11.020_bb0570","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1365-2362.1970.tb00591.x","article-title":"The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo","volume":"1","author":"Fleisch","year":"1970","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.bone.2010.11.020_bb0575","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1161\/01.ATV.21.5.817","article-title":"Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption","volume":"21","author":"Price","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.bone.2010.11.020_bb0580","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s00223-002-1006-9","article-title":"The amino bisphosphonate ibandronate prevents calciphylaxis in the rat at doses that inhibit bone resorption","volume":"71","author":"Price","year":"2002","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.bone.2010.11.020_bb0585","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1093\/ndt\/gfh305","article-title":"Rapid improvement of calciphylaxis after intravenous pamidronate therapy in a patient with chronic renal failure","volume":"19","author":"Monney","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.bone.2010.11.020_bb0590","first-page":"554","article-title":"Successful treatment of calciphylaxis with pamidronate","volume":"18","author":"Schliep","year":"2008","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.bone.2010.11.020_bb0595","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2174\/157489206778776989","article-title":"Last generation of amino-bisphosphonates (N-BPs) and cancer angio-genesis: a new role for these drugs?","volume":"1","author":"Santini","year":"2006","journal-title":"Recent Pat Anticancer Drug Discov"},{"key":"10.1016\/j.bone.2010.11.020_bb0600","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.canlet.2007.07.007","article-title":"Bisphosphonates in cancer therapy","volume":"257","author":"Stresing","year":"2007","journal-title":"Cancer Lett"},{"key":"10.1016\/j.bone.2010.11.020_bb0605","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1359\/JBMR.040305","article-title":"A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women","volume":"19","author":"Bekker","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.11.020_bb0610","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1185\/030079904125004475","article-title":"Bone safety of long-term bisphosphonate treatment","volume":"20","author":"Rodan","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.bone.2010.11.020_bb0615","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF02408534","article-title":"Kinetic studies of bone and mineral metabolism during treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) in rats","volume":"32","author":"Reitsma","year":"1980","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.bone.2010.11.020_bb0620","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten years' experience with alendronate for osteoporosis in postmenopausal women","volume":"350","author":"Bone","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2010.11.020_bb0625","first-page":"3109","article-title":"Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group","volume":"85","author":"Tonino","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2010.11.020_bb0630","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1007\/s00198-004-1602-9","article-title":"Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study","volume":"15","author":"Delmas","year":"2004","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2010.11.020_bb0635","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S8756-3282(02)00946-8","article-title":"Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience","volume":"32","author":"Sorensen","year":"2003","journal-title":"Bone"},{"key":"10.1016\/j.bone.2010.11.020_bb0640","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00223-004-0039-7","article-title":"Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis","volume":"75","author":"Ste-Marie","year":"2004","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.bone.2010.11.020_bb0645","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/8756-3282(95)00445-9","article-title":"Bisphosphonates: a review of their pharmacokinetic properties","volume":"18","author":"Lin","year":"1996","journal-title":"Bone"},{"key":"10.1016\/j.bone.2010.11.020_bb0650","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1359\/jbmr.1997.12.10.1700","article-title":"Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis","volume":"12","author":"Khan","year":"1997","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.11.020_bb0655","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s00228-001-0411-8","article-title":"A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis","volume":"57","author":"Cremers","year":"2002","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.bone.2010.11.020_bb0660","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1359\/jbmr.2003.18.5.852","article-title":"Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats","volume":"18","author":"Capparelli","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.11.020_bb0665","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1359\/jbmr.080109","article-title":"RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats","volume":"23","author":"Ominsky","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.11.020_bb0670","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1172\/JCI11296","article-title":"Activated parathyroid hormone\/parathyroid hormone-related protein receptor in osteoblastic cells differentially affects cortical and trabecular bone","volume":"107","author":"Calvi","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bone.2010.11.020_bb0675","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.2353\/ajpath.2009.081026","article-title":"Osteoprotegerin abrogated cortical porosity and bone marrow fibrosis in a mouse model of constitutive activation of the PTH\/PTHrP receptor","volume":"174","author":"Ohishi","year":"2009","journal-title":"Am J Pathol"},{"key":"10.1016\/j.bone.2010.11.020_bb0680","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0021-9290(01)00203-2","article-title":"Mechanical properties in long bones of rat osteopetrotic mutations","volume":"35","author":"J\u00e4ms\u00e4","year":"2002","journal-title":"J Biomech"},{"key":"10.1016\/j.bone.2010.11.020_bb0685","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1359\/jbmr.070720","article-title":"Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment","volume":"22","author":"Allen","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.11.020_bb0690","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1359\/jbmr.2003.18.3.512","article-title":"Long-term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra","volume":"18","author":"Komatsubara","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.11.020_bb0695","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1359\/JBMR.040126","article-title":"Suppressed bone turnover by long-term bisphosphonate treatment accumulates microdamage but maintains intrinsic material properties in cortical bone of dog rib","volume":"19","author":"Komatsubara","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.11.020_bb0700","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1359\/jbmr.2000.15.4.613","article-title":"Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib","volume":"15","author":"Mashiba","year":"2000","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.11.020_bb0705","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s12018-008-9015-5","article-title":"Skeletal microdamage: less about biomechanics and more about remodeling","volume":"6","author":"Allen","year":"2008","journal-title":"Clin Rev Bone Miner Metab"},{"key":"10.1016\/j.bone.2010.11.020_bb0710","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1359\/jbmr.080307","article-title":"Low bone turnover and microdamage? How and where to assess it?","volume":"23","author":"Burr","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.11.020_bb0715","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1007\/s00198-009-0899-9","article-title":"Bone microdamage: a clinical perspective","volume":"20","author":"Chapurlat","year":"2009","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2010.11.020_bb0720","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1359\/jbmr.090527","article-title":"Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate","volume":"24","author":"Dobnig","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.11.020_bb0725","doi-asserted-by":"crossref","first-page":"4466","DOI":"10.1210\/en.2007-0229","article-title":"The effects of combination of alendronate and human parathyroid hormone(1\u201334) on bone strength are synergistic in the lumbar vertebra and additive in the femur of C57BL\/6J mice","volume":"148","author":"Johnston","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.bone.2010.11.020_bb0730","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.bone.2007.11.017","article-title":"Parathyroid hormone mediates bone growth through the regulation of osteoblast proliferation and differentiation","volume":"42","author":"Pettway","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.bone.2010.11.020_bb0735","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","author":"Black","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2010.11.020_bb0740","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/art.24445","article-title":"Prevention of glucocorticoid-induced bone loss in mice by inhibition of RANKL","volume":"60","author":"Hofbauer","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.bone.2010.11.020_bb0745","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1359\/jbmr.081113","article-title":"Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing","volume":"24","author":"Gerstenfeld","year":"2009","journal-title":"J Bone Miner Res"},{"issue":"Suppl 1","key":"10.1016\/j.bone.2010.11.020_bb0750","article-title":"Denosumab (AMG 162), a fully human RANKL antibody, improves cortical and cancellous bone mass and bone strength in ovariectomized cynomolgus monkeys","volume":"22","author":"Ominsky","year":"2007","journal-title":"J Bone Miner Res"},{"issue":"Suppl 1","key":"10.1016\/j.bone.2010.11.020_bb0755","article-title":"Decreased fluorochrome labeling in bone biopsies from denosumab-treated cynomolgus monkeys is related to reductions in cortical porosity and trabecular eroded surfaces","volume":"24","author":"Ominsky","year":"2009","journal-title":"J Bone Miner Res"},{"issue":"Suppl 1","key":"10.1016\/j.bone.2010.11.020_bb0760","first-page":"S61","article-title":"Transition from alendronate to denosumab resulted in further reductions in local and systemic bone turnover parameters and reduced cortical porosity in ovariectomized cynomolgus monkeys","volume":"23","author":"Ominsky","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.11.020_bb0765","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.11.020_bb0770","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2010.11.020_bb0775","first-page":"1895","article-title":"Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group","volume":"85","author":"Fogelman","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2010.11.020_bb0780","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM199007123230201","article-title":"Intermittent cyclical etidronate treatment of postmenopausal osteoporosis","volume":"323","author":"Watts","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2010.11.020_bb0785","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2010.11.020_bb0790","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.bone.2010.11.020_bb0795","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group","volume":"333","author":"Liberman","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2010.11.020_bb0800","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2010.11.020_bb0805","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1359\/jbmr.0809010","article-title":"Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial","volume":"24","author":"Brown","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.11.020_bb0810","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1359\/jbmr.090716","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy","volume":"25","author":"Kendler","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.11.020_bb0815","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","article-title":"Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial","volume":"43","author":"Miller","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.bone.2010.11.020_bb0820","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1002\/jbmr.81","article-title":"Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate","volume":"25","author":"Seeman","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.11.020_bb0825","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.bone.2010.04.594","article-title":"Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density","volume":"47","author":"Genant","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.bone.2010.11.020_bb0830","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1138\/20100444","article-title":"Bisphosphonates and denosumab: do they thicken bone cortices, and can these changes be assessed by high-resolution pQCT?","volume":"7","author":"Ferrari","year":"2010","journal-title":"IBMS BoneKEy"},{"key":"10.1016\/j.bone.2010.11.020_bb0835","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1359\/jbmr.090711","article-title":"Risedronate reduces intracortical porosity in women with osteoporosis","volume":"25","author":"Borah","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.11.020_bb0840","first-page":"325","article-title":"Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis","volume":"6","author":"Pazianas","year":"2010","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.bone.2010.11.020_bb0845","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.bone.2010.11.020_bb0850","doi-asserted-by":"crossref","first-page":"864","DOI":"10.14219\/jada.archive.2009.0280","article-title":"Bisphosphonate and nonbisphosphonate-associated osteonecrosis of the jaw: a review","volume":"140","author":"Almazrooa","year":"2009","journal-title":"J Am Dent Assoc"},{"key":"10.1016\/j.bone.2010.11.020_bb0855","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.bjoms.2009.08.030","article-title":"Osteonecrosis of the jaws induced by anti-RANK ligand therapy","volume":"48","author":"Taylor","year":"2010","journal-title":"Br J Oral Maxillofac Surg"},{"key":"10.1016\/j.bone.2010.11.020_bb0860","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.joms.2009.10.010","article-title":"Osteonecrosis of the jaw in a patient on denosumab","volume":"68","author":"Aghaloo","year":"2010","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.bone.2010.11.020_bb0865","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00198-008-0560-z","article-title":"European guidance for the diagnosis and management of osteoporosis in postmenopausal women","volume":"19","author":"Kanis","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2010.11.020_bb0870","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1210\/jc.2004-0952","article-title":"Severely suppressed bone turnover: a potential complication of alendronate therapy","volume":"90","author":"Odvina","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2010.11.020_bb0875","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1359\/jbmr.081247","article-title":"Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study","volume":"24","author":"Abrahamsen","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.11.020_bb0880","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1600-0773.1997.tb01964.x","article-title":"Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models","volume":"80","author":"Green","year":"1997","journal-title":"Pharmacol Toxicol"},{"key":"10.1016\/j.bone.2010.11.020_bb0885","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/ki.2008.356","article-title":"Bisphosphonate nephrotoxicity","volume":"74","author":"Perazella","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.bone.2010.11.020_bb0890","author":"Genentech Inc."},{"key":"10.1016\/j.bone.2010.11.020_bb0895","author":"Genentech Inc"},{"key":"10.1016\/j.bone.2010.11.020_bb0900","author":"Merck and Co. Inc"},{"key":"10.1016\/j.bone.2010.11.020_bb0905","author":"Novartis Pharmaceuticals Corporation"},{"key":"10.1016\/j.bone.2010.11.020_bb0910","author":"Warner Chilcott Pharmaceuticals Inc."},{"key":"10.1016\/j.bone.2010.11.020_bb0915","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1359\/jbmr.070112","article-title":"Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial","volume":"22","author":"Jamal","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.11.020_bb0920","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1359\/JBMR.050817","article-title":"Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials","volume":"20","author":"Miller","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"Suppl 1","key":"10.1016\/j.bone.2010.11.020_bb0925","first-page":"SA402","article-title":"Renal safety across a wide range of dosing regimens of risedronate","volume":"23","author":"Miller","year":"2008","journal-title":"J Bone Miner Res"},{"issue":"Suppl 1","key":"10.1016\/j.bone.2010.11.020_bb0930","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.1016\/j.bone.2010.04.491","article-title":"The effects of denosumab on bone mineral density (BMD) and fracture by level of renal function","volume":"47","author":"Jamal","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.bone.2010.11.020_bb0935","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1359\/jbmr.091009","article-title":"Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo","volume":"25","author":"Roelofs","year":"2010","journal-title":"J Bone Miner Res"},{"issue":"Suppl 2","key":"10.1016\/j.bone.2010.11.020_bb0940","doi-asserted-by":"crossref","first-page":"S437","DOI":"10.1007\/s00198-010-1250-1","article-title":"Comparing and contrasting the effects of strontium ranelate and other osteoporosis drugs on microarchitecture","volume":"21","author":"Ferrari","year":"2010","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2010.11.020_bb0945","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1172\/JCI119668","article-title":"Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis","volume":"100","author":"Chavassieux","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bone.2010.11.020_bb0950","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.bone.2009.11.004","article-title":"Effects of intermittent intravenous ibandronate injections on bone quality and micro-architecture in women with postmenopausal osteoporosis: the DIVA study","volume":"46","author":"Recker","year":"2010","journal-title":"Bone"},{"issue":"Suppl 1","key":"10.1016\/j.bone.2010.11.020_bb0955","first-page":"S40","article-title":"The effects of alendronate or denosumab on cortical and trabecular bone mass, bone strength, and bone mass\u2013strength relationships in mice","volume":"23","author":"Ominsky","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.11.020_bb0960","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11914-009-0004-5","article-title":"Denosumab: anti-RANKL antibody","volume":"7","author":"Miller","year":"2009","journal-title":"Curr Osteoporos Rep"},{"key":"10.1016\/j.bone.2010.11.020_bb0965","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/8756-3282(96)00182-2","article-title":"Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones","volume":"19","author":"Masarachia","year":"1996","journal-title":"Bone"},{"key":"10.1016\/j.bone.2010.11.020_bb0970","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11914-006-0012-7","article-title":"Inhibition of RANKL as a treatment for osteoporosis: preclinical and early clinical studies","volume":"4","author":"McClung","year":"2006","journal-title":"Curr Osteoporos Rep"},{"key":"10.1016\/j.bone.2010.11.020_bb0975","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/8756-3282(95)00428-9","article-title":"Inhibitory effects of bisphosphonate (YM175) on bone resorption induced by a metastatic bone tumor","volume":"18","author":"Hiraga","year":"1996","journal-title":"Bone"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S875632821002051X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S875632821002051X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T04:25:20Z","timestamp":1544070320000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S875632821002051X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":195,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["S875632821002051X"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2010.11.020","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]}}}